Director Sales Cast a Shadow on Olema Pharmaceuticals' Bullish Outlook

Related Articles

Eos Energy's Insider Sales Cast a Shadow on its Growth Story

1 months ago

PriceSmart's Insider Sales Cast a Shadow on Strong Q2 Growth

1 months ago

Insider Exodus at World Acceptance: Why Director Sales Cast a Shadow on WRLD's Rally

2 months ago

Ultra Clean Holdings: Insider Sales Cast a Shadow on a Soaring Stock

2 months ago

Category

You may also like

Stock News•1 week ago

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

Arrowhead Pharmaceuticals director sold 11,600 shares for $1 million, reducing direct holdings by 9%. The insider sale may signal mixed sentiment ahead of upcoming clinical data readouts.

ARWR

Share

Stock News•1 months ago

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Pharmaceuticals (OLMA) shares fell Tuesday after the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in Q1 2027.

OLMA

Share

Stock News•1 months ago

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

A Corcept director sold 10,000 shares at $88.30 for $883,000 on July 15, 2026, reducing indirect holdings by 0.67%.

CORT

Share